Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
Mitochondrial DNA deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial DNA deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melanoma skin cancer are provided.
1. A method of detecting a deletion spanning approximately nucleotides 10744 to 14124 of the human mtDNA genome, wherein said deletion is associated with prostate cancer, in a subject having mtDNA, comprising:
(a) providing a biological sample from the subject;
(b) extracting mtDNA from the biological sample; and
(c) detecting the presence of the deletion in the mtDNA.
2. The method of claim 1 , wherein the deletion is approximately 3379 bp.
3. The method of claim 1 , wherein the deletion comprises substantially genes encoding NADH dehydrogenase subunit 4L, NADH dehydrogenase subunit 4, NADH dehydrogenase subunit 5, tRNA histidine, tRNAserine2, and tRNA Ieucine2.
4. The method of claim 1 , wherein the step of detecting the presence of the deletion in the mtDNA comprises PCR analysis selected from the group consisting of deletion specific PCR analysis, radioactive PCR analysis, quantitative PCR and real-time PCR (RT-PCR) analysis.
5. The method of claim 4 , wherein the PCR analysis is quantitative PCR or RT-PCR comprising amplification of a portion of the mtDNA using a recombinant, thermostable, Taq DNA polymerase.
6. The method of claim 4 wherein the PCR analysis comprises amplification of a portion of the mtDNA with a PCR forward primer having a sequence corresponding to SEQ ID NO: 139.
7. The method of claim 4 , wherein a PCR primer that bridges the mtDNA junction formed by the deletion spanning approximately nucleotides 10744 to 14124 is used.
8. The method of claim 4 , wherein the PCR analysis is quantitative PCR analysis comprising use of a primer that bridges the mtDNA junction formed by the deletion spanning approximately nucleotides 10744 to 14124.
9. The method of claim 1 , wherein the method is used to detect prostate cancer, a predisposition to prostate cancer or the progression of prostate cancer.
10. The method of claim 1 , wherein the step of detecting the presence of the deletion in the mtDNA comprises PCR analysis using a primer that bridges the mtDNA junction formed by the deletion spanning approximately nucleotides 10744 to 14124.
11. A method comprising detection of an mtDNA deletion spanning approximately nucleotides 10744 to 14124 of the human mtDNA genome as a biomarker for prostate cancer.
12. The method of claim 11 , wherein the deletion is approximately 3379 bp.
13. The method of claim 11 , wherein the deletion is detected in malignant tissue, adjacent benign tissue, distant benign tissue, precursor lesions, prostate massage fluid, urine, post-DRE urine, or blood, in a subject having prostate cancer or progressing toward prostate cancer or a subject without prostate cancer.
14. A method for confirming or refuting a prostate cancer biopsy test from a biopsy sample, comprising:
(a) obtaining a normal tissue from a biopsy sample; and
(b) detecting the absence or presence of a human mtDNA deletion at approximately nucleotides 10744 to 14124 of the human mtDNA genome in the normal tissue.
15. A method for three-dimensional prostate tumour mapping, comprising:
(a) obtaining sextant needle biopsy samples;
(b) extracting mtDNA from the biological samples; and
(c) detecting the absence or presence of a deletion spanning approximately nucleotides 10744 to 14124 of the human mtDNA genome in each of the sextant samples.
16. A method for diagnosing prostate cancer, comprising hybridizing nucleic acids to an array, wherein the array comprises at least one nucleic acid member, and a solid substrate, wherein the at least one nucleic acid member is associated with a human mtDNA deletion at approximately nucleotides 10744 to 14124 of the human mtDNA genome, wherein the at least one nucleic acid member has a unique position on said array and is stably associated with the solid substrate.
17. A method for diagnosing prostate cancer comprising using a kit, wherein the kit comprises an array comprising at least one nucleic acid member and a solid substrate, wherein the at least one nucleic acid member is associated with a human mtDNA deletion at approximately nucleotides 10744 to 14124 of the human mtDNA genome, wherein the at least one nucleic acid member has a unique position on said array and is stably associated with the solid substrate and at least one member selected from the group consisting of: a disposable chip, means for holding the solid support, means for extraction of mitochondrial DNA, primers, reagents and instructions.